Dermot began his career as a biochemist with Schering-Plough Pharmaceuticals in their state-of-the-art bio-manufacturing facility in Cork, Ireland. After moving to California in 1994, Dermot quickly transitioned from the laboratory to operations and project management with Syntex, Roche, and Yamanouchi. Dermot’s commitment to the impact of process re-engineering was strengthened during his leadership of the automation of the monoclonal antibody production process at Medarex (acquired by Bristol-Myers Squibb in 2008), combining process re-engineering, custom software development, integration, and massive change management to allow four technicians to produce nine times more R&D samples than sixty scientists had produced prior to automation.
Dermot joined Singularity in 2016. Leveraging rapid prototyping, experimentation and customer-focused development to build dynamic tools and interfaces, Dermot is creating the infrastructure and operational effectiveness needed to scale SU’s global community of customers, experts and partners. Today Dermot leads the day-to-day operations of Singularity Group and is driving the recovery post-Covid. Dermot received his B.S. and M.S. degrees in Biochemistry from National University (Galway, Ireland) and his MBA from Pepperdine University